Neuropace Inc expected to post a loss of 22 cents a share - Earnings Preview

NeuroPace

28/02/2025 22:02

Neuropace Inc NPCE.OQ NPCE.O is expected to show a rise in quarterly revenue when it reports  results on March 4 for the period ending December 31 2024

The Mountain View California-based  company is expected to report a 17.5% increase in revenue to $21.172 million from $18.01 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Neuropace Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Neuropace Inc is $18.00​, above​ its last closing price of $12.56. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.27
-0.27
-0.19
Beat
29.2
Jun. 30 2024
-0.30
-0.30
-0.26
Beat
13.3
Mar. 31 2024
-0.32
-0.32
-0.32
Met
0.5​
Dec. 31 2023
-0.30
-0.31
-0.23
Beat
27
​​Sep. 30 2023
-0.41
-0.41
-0.28
Beat
31.7
Jun. 30 2023
-0.46
-0.46
-0.36
Beat
22.6​
Mar. 31 2023
-0.46
-0.46
-0.41
Beat
10.1
Dec. 31 2022
-0.50
-0.49
-0.45
Beat
9.1

This summary was machine generated February 28 at 22:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)